(No subject)

January 7, 2009

My son's immuno asked us if we wanted our son to participate in this

trial. The way it was discribed to me was the Enhaze would be

delivered to the site first and then you would start the IgG in the

same site without repoking. The Enhaze was discribed as a solution

that loosens up the tissue and allows more of the SCIG fluid to be

infused into one site allowing you to do a larger dose to cover the

whole month rather that just the week. I would imagine there is an

upper limit to how much can be infused in one site, so it would

depend on the dosage as to how many sites a particular person would

need.

Unfortunately we had to decline the offer to participate in the study

since it would require frequent IgG level blood draws which are very

traumatic for my son. But it sounds like a wonderful technical

advancement in SubQ and I am looking forward to hearing about the

results.

- Amy, mom to Nolan, age 4

>

> Phase III Trial Begins For GAMMAGARD LIQUID Plus RHuPH20 In Primary

Immunodeficiency Patients

>

> The way this reads is that it is still a 10% solution but they are

putting an enzyme with the Gamma Liquid to allow the absorption to be

different.

>

> What I'm curious about is the following statement:

>

> " Subcutaneous (SC) administration of GAMMAGARD LIQUID with Enhanze

Technology is an investigational study and when approved could allow

patients to receive a full monthly dose in a single injection site in

their home setting. "

> Do they really mean you could do the full monthly in a single subq

site and only once a month?

>

> Other member please read the press release and see what you make of

it.

>

> Ursula - mom to (16) and Macey (13,CVID)

>

Recommended Posts